Silexion Therapeutics Shares Encouraging Preclinical Findings on SIL204's Effectiveness and Distribution in Key Metastatic Sites of Pancreatic Cancer After Systemic Delivery
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 10 2025
0mins
Source: Globenewswire
New Preclinical Data: Silexion Therapeutics announced successful preclinical results showing that their drug SIL204 effectively targets primary and metastatic sites of pancreatic cancer, achieving measurable reductions in tumor burden after subcutaneous administration.
Clinical Trial Timeline: The company is on track to initiate Phase 2/3 clinical trials in the first half of 2026, with regulatory submissions planned for late 2025 and early 2026, further validating their dual-route administration strategy for treating KRAS-driven cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
